Skip to main content
. 2012 Apr 17;9:16. doi: 10.1186/1550-2783-9-16

Table 1.

Pharmacokinetic parameters for uric acid and lithium after oral administration of ATP

Mode of administration (time period) AUC uric acid mmol.min/L Cmaxmmol/L (range) tmaxmin (range) AUC Lithium mmol.min
Naso-duodenal tube
ATP (270 min)
19.6 ± 4.4 a,b,c
0.31 ± 0.03
135
n.a.
 
 
(0.23-0.38)
(105–240)
 
Placebo (270 min)
−0.4 ± 0.4
0.21 ± 0.03
n.a.
n.a.
 
 
(0.15-0.33)
 
 
Proximal-release pellets
 
 
 
 
ATP (270 min)
16.1 ± 3.0
n.a.
n.a.
n.a.
Placebo (270 min)
0.8 ± 0.9
n.a.
n.a.
n.a.
ATP (420 min)
25.4 ± 5.7 d,e
0.30 ± 0.03
240
65174 ± 7985 f
 
 
(0.21-0.41)
(165–390)
 
Placebo (420 min)
0.9 ± 1.1
0.20 ± 0.02
n.a.
117914 ± 15021 f
 
 
(0.16-0.31)
 
 
Distal-release pellets
 
 
 
 
ATP (270 min)
1.7 ± 1.1
n.a.
n.a.
n.a.
ATP (420 min)
3.2 ± 1.4
0.22 ± 0.02
390
12575 ± 2832 f
    (0.17-0.34) (105–420)  

Values are group means ± SEM, n = 8 per formulation, P-values are based on paired-samples t-tests. N.a. = not available.

a Different from naso-duodenal tube placebo (P = 0.002), b Different from ATP distal-release pellets 270 min (P = 0.007), c Different from proximal-release placebo pellets 270 min (P = 0.007) d Different from ATP distal release pellets 420 min (P = 0.005), e Different from proximal-release placebo pellets (P = 0.005), f Different from each other (P < 0.001).